On July 21, 2022 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported its founding affiliation with Bakar Labs, the incubator at UC Berkeley’s Bakar BioEnginuity Hub (Press release, BridgeBio, JUL 21, 2022, View Source [SID1234616871]). Bakar Labs was established by the University of California (UC), Berkeley and QB3, UC’s research institute for innovation and entrepreneurship in the life sciences and is open to academic researchers from around the world. The Labs will host up to 50 innovative life science start-up companies seeking to advance promising research.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Partnering with UC Berkeley and QB3 to launch Bakar Labs is a natural extension of our mission to discover, create, test, and deliver transformative medicines to as many patients as possible. Through this collaboration, we aim to strengthen the Bay Area biotech ecosystem and potentially unlock new therapies for patients with unmet needs," said BridgeBio founder and CEO Neil Kumar, Ph.D.
The multi-disciplinary startup companies at Bakar Labs are supported by world-class facilities, resources, and expertise from industry and academia. BridgeBio intends to review discoveries, provide support to entrepreneurs, and consider possible partnership opportunities with startups focused on potential therapies for patients with genetically-driven diseases and cancers.
"We admire BridgeBio’s innovation in pioneering a decentralized model with shared resources, addressing vital unmet needs for therapies for genetic diseases," said Regis Kelly, Ph.D., OBE, director of Bakar Labs. "We look forward to learning from and interacting with BridgeBio as we develop Bakar Labs as a shared resource for entrepreneurs developing a wide range of new biotechnologies."
A core part of BridgeBio’s efforts to help patients is the identification of new discoveries in academia. With an extensive pipeline and research and development capabilities, BridgeBio seeks to provide the insights and support needed to rapidly progress promising academic research from labs to clinical development. This new partnership will allow the Company to play a role in finding and accelerating research for patients as quickly and safely as possible.